Related Experiment Videos

Cromolyn and nedocromil therapy of asthmatic children

C T Furukawa1

  • 1University of Washington, School of Medicine, Seattle.

Allergy Proceedings : the Official Journal of Regional and State Allergy Societies
|May 1, 1989
PubMed

Insights

Cromolyn treatment for children with asthma significantly reduces asthma symptoms and bronchial hyperreactivity. It also mitigates beta-receptor desensitization from beta-adrenergic drugs, offering a safer, effective asthma management option.

Area of Science:

  • Pediatric Pulmonology
  • Allergy and Immunology
  • Pharmacology

Background:

  • Asthma in children presents significant health challenges.
  • Current asthma treatments have limitations and potential side effects.
  • Cromolyn sodium is an established antiasthmatic medication.

Purpose of the Study:

  • To evaluate the efficacy of cromolyn in pediatric asthma patients.
  • To assess the impact of cromolyn on bronchial hyperreactivity.
  • To investigate cromolyn's role in mitigating side effects of beta-adrenergic agonists.

Main Methods:

  • Analysis of controlled studies involving cromolyn treatment in asthmatic children.
  • Assessment of asthma symptom frequency and severity.
  • Measurement of bronchial hyperreactivity.
  • Evaluation of beta-receptor sensitivity during concomitant medication use.

Main Results:

  • Cromolyn treatment for over two months led to decreased asthma symptoms.
  • Significant reduction in bronchial hyperreactivity was observed.
  • Concomitant cromolyn use with beta-adrenergic drugs abated reduced beta-receptor sensitivity.

Conclusions:

  • Cromolyn offers significant benefits for managing pediatric asthma.
  • Its safety profile is a key advantage.
  • Further research into related antiasthmatic medications like nedocromil is warranted.

Related Concept Videos